Send the following on WhatsApp
Continue to Chathttps://it.marketscreener.com/quotazioni/azione/ALPHAMAB-ONCOLOGY-103501724/attualita/Alphamab-Oncology-annuncia-il-dosaggio-della-prima-paziente-nello-studio-di-fase-Iii-di-Jskn003-per-45492584/?utm_source=whatsapp&utm_medium=social&utm_campaign=share